30results about How to "Novel sequence" patented technology

A DNA, which encodes the following polypeptide (a), (b), (c) or (d):(a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2 or 4,(b) a polypeptide consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 4 by deletion, substitution or addition of one or several amino acids, and having hypophosphatemia-inducing activity, phosphate transport-suppressing activity, calcification-suppressing activity or in vivo vitamin D metabolism-regulating activity,(c) a polypeptide consisting of a partial sequence of the amino acid sequence represented by SEQ ID NO: 2, wherein the above partial sequence contains an amino acid sequence at least ranging from the 34th to 201st amino acids in the above amino acid sequence, or(d) a polypeptide consisting of a partial sequence of the amino acid sequence represented by SEQ ID NO: 2, wherein the above partial sequence:(i) contains an amino acid sequence ranging from at least the 34th to 201st amino acids in said amino acid sequence,(ii) consists of an amino acid sequence derived from the partial sequence by deletion, substitution, or addition of one or several amino acids, and(iii) has hypophosphatemia-inducing activity, phosphate transport-suppressing activity, calcification-suppressing activity or in vivo vitamin D metabolism-regulating activity.

The invention relates to the technical field of biotechnology and biochemical detection, and in particular relates to alginate lyase and an application thereof in quantitative detection of alginate. The alginate lyase Aly7A has a novel amino acid sequence and good enzymatic properties, and the amino acid sequence of the alginate lyase Aly7A is SEQ ID NO. 1. On the basis of Aly7A, the invention discloses a quantitative detection method of alginate. The method comprises the steps that alginate lyase Aly7A and a sample to be detected are subjected to mixed reaction; alginate possibly contained inthe sample is subjected to enzymolysis; the increment of the light absorption value of a reaction system at 235 nm is detected and substituted into a standard curve; and the content of alginate in the sample to be detected can be detected. The detection method has the advantages of being high in specificity, rapid, easy and convenient to implement and the like.

The invention belongs to the technical field of biology, particularly relates to an anti-TROP2 nano antibody composed of a variable region of a heavy-chain antibody and a preparation method and application of the anti-TROP2 nano antibody, and also provides a coding nucleic acid molecule, an expression vector, a host cell and the like of the antibody. The anti-TROP2 nano-antibody (TROP2-VHH-01-9F nano-antibody and TROP2-VHH-01-5A nano-antibody) prepared by the invention has high affinity binding to a human TROP2 antigen, also has strong antibody endocytosis activity and a novel sequence, and isa new anti-TROP2 nano-antibody.

The invention belongs to the technical field of biology, relates to an anti-human SIRP alpha monoclonal antibody and application thereof, and also provides a coding nucleic acid molecule, an expression vector and a host cell of the antibody, and a method for expressing the antibody. The invention also provides an antibody immunoconjugates comprising the antibody of the invention, bispecific molecules, a chimeric antigen receptor, a pharmaceutical composition, and a diagnosis and treatment method. According to the invention, the human SIRP alpha monoclonal antibody can be specifically recognized, the affinity of the antibody and the human SIRP alpha is higher than that of an existing anti-human SIRP alpha monoclonal antibody, and the sequence is novel.

The invention relates to an anti-human PD1 monoclonal antibody and application thereof, also provides coding nucleic acid molecules of the antibody, expression carriers, host cells and a method for expressing the antibody, and also provides an antibody immune coupling binder of the antibody, bispecific molecules, chimeric antigen receptors, a pharmaceutical composition and application. Compared with the prior art, the anti-human PD1 monoclonal antibody disclosed by the invention has the following advantages that the monoclonal antibody of human PD1 can be specially identified, and the bindingaffinity of the antibody and the human PD1 is stronger than that of an existing anti-human PD1 monoclonal antibody, and a sequence of the antibody is novel.

The invention provides a marine-derived bacillus antimicrobial protein MD and a preparation method thereof and relates to a marine-derived bacillus antimicrobial protein. Supernatant is taken after bacillus culture, ammonium sulfate is added to reach the saturation of 60%, centrifugation is performed, a precipitate is taken and is dissolved in water again, dialysis, lyophilization and re-dissolution are performed to obtain a crude protein solution, then separation and purification are performed on an ethyl amino ethyl anion exchange chromatographic column, components are collected, and a staphylococcus aureus is used as a tested indicator bacterium to track active components after centrifugal ultra-filtration and concentration; the concentrated active components are separated and purified on a quaternary ammonium salt strong anion exchange column, elution components are collected, ultra-filtration and concentration are performed, the bacteriostatic activity is checked, and the component purity is judged through SDS-PAGE electrophoresis after the active components are determined; single strips on an SDS-PAGE electrophoretogram are cut to perform liquid chromatography-mass spectrometry combined detection and identification, and a whole genome encoding protein sequence is used as a database to perform comparison so as to obtain the antimicrobial protein sequence MD.

The invention relates to an anti-human CSF-1R monoclonal antibody and application. Meanwhile, the invention provides a coding nucleic acid molecule of the antibody, an expression vector, a host cell and a method which is used for expressing the antibody. The invention further provides an antibody immunoconjugate, a bi-specific molecule, a chimeric antigen receptor, a medicine compound and application of the antibody. Compared with the prior art, the anti-human CSF-1R monoclonal antibody has the following advantages that the monoclonal antibody can specifically recognize human CSF-1R, the binding affinity of the antibody and the human CSF-1R is higher than those of existing anti-human CSF-1R monoclonal antibodies, sequences of the anti-human CSF-1R monoclonal antibody are novel, and the anti-human CSF-1R monoclonal antibody bonds a unique epitope.

The invention provides an antibody calculation optimization method based on a genetic algorithm. The method covers algorithms such as peptide chain processing, epitope recognition, sequence annotation, CDR H3 sequence design, antibody modeling, molecular docking, antibody property evaluation and the like, and has a full-process automatic antibody design function. Based on known antibody sequence data, a variant antibody sequence formed by combining random sites and random residues is iteratively generated and evaluated by utilizing a genetic algorithm aiming at a heavy-chain highly variable H3section (CDR H3) of the antibody and is subjected to comprehensive scoring comparison with an original antibody, so that an optimized antibody is obtained or a low-quality antibody is removed, and finally, a candidate antibody sequence library is generated, and the biophysical property of the candidate antibody is predicted. According to the invention, basic elements of an antibody calculation optimization process are integrated, and automation of the process is realized on the same platform.

The invention relates to a chitosanase CsnA1 derived from deep-sea microorganisms and an application thereof. The amino acid sequence of the chitosanase CsnA1 is shown in SEQ ID NO.1. The invention provides a fermentation and purification method of chitosanase CsnA1, the enzyme activity of the fermentation liquid is as high as 379.9 U / mL, the purity of one-step purification is >95%, and the recovery rate is 93.7%. The chitosanase CsnA1 of the present invention has psychrophilic properties, the optimum reaction temperature is 25°C, and the detection activity at 0°C, 10°C, and 15°C can reach 67.6%, 81.5% and 89.3% of the optimum reaction temperature . The chitosanase CsnA1 degrades chitobiose and chitotriose as main products, and has good application potential.

The invention relates to an anti-human CSF-1R monoclonal antibody and an application thereof. The invention also provides an encoded nucleic acid molecule of the antibody, an expression vector, a hostcell and a method of expressing the antibody. The invention also provides an antibody somatic immunoconjugate, double specific molecules, an embedded antigen acceptor, a pharmaceutical composition and an application of the antibody. Compared with the prior art, the antibody has the advantages that the human CSF-1R monoclonal antibody can be recognized specifically. The affinity of the antibody combined with CSF-1R is stronger than that of an existing anti-human CSF-1R monoclonal antibody, and the antibody is combined with a unique epitope and is novel in sequence.

The invention relates to an anti-human CSF-1R monoclonal antibody and application thereof and simultaneously discloses an encoding nucleic acid molecule, an expression vector, a host cell of the antibody and a method for expressing the antibody. The invention further provides an antibody immune coupling conjugate, a bi-specific molecule, a chimeric antigen receptor and a pharmaceutical compositionwhich contains the antibody and use. Compared with the prior art, the antibody has the advantages that the monoclonal antibody is capable of specifically recognizing human CSF-1R, the bonding affinity between the monoclonal antibody and human CSF-1R is stronger than that between an existing anti-human CSF-1R monoclonal antibody and human CSF-1R, and the sequence is novel.

The invention relates to an anti-human PD1 monoclonal antibody and a use thereof as well as provides an encoded nucleic acid molecule, an expression vector and a host cell of the antibody and a methodfor expressing the antibody. The invention also provides an antibody immune coupling conjugate, a bi-specific molecule, a chimeric antigen receptor and a drug composition of the antibody and uses ofthe antibody immune coupling conjugate, the bi-specific molecule, the chimeric antigen receptor and the drug composition. Compared with the prior art, the use can specifically recognize a human PD1 monoclonal antibody, the affinity of the antibody binding with human PD1 is stronger than the existing anti-human PD1 monoclonal antibody, and a sequence of the antibody is novel.

The invention belongs to the technical field of biology, relates to an anti-human SIRP alpha monoclonal antibody and application thereof, and also provides coding nucleic acid molecules, an expressionvector and a host cell of the antibody, and a method for expressing the antibody. The invention also provides an antibody immunoconjugate containing the antibody, bispecific molecules, a chimeric antigen receptor, a pharmaceutical composition, and a diagnosis and treatment method. According to the monoclonal antibody capable of specifically recognizing human SIRP alpha, the affinity of combiningthe antibody with the human SIRP alpha is higher than that of existing anti-human SIRP alpha monoclonal antibodies, and the sequence is novel.

The invention relates to algin lyase having a heat recovery characteristic and an application of the algin lyase. The algin lyase is algin lyase AlyL05, and the amino acid sequence is shown as SEQ IDNO.1. The similar degree of the amino acid sequence of the algin lyase provided by the invention and the sequence of conventional algin lyase having known functions is only 49%. The algin lyase AlyL05disclosed by the invention has heat recovery properties; after the algin lyase AlyL05 is boiled over for 5 minutes, the boiled-over algin lyase AlyL05 is put on ice for incubation for 30 minutes, and58.3% of activity can be recovered. An enzymatic degradation main product includes unsaturated algin disaccharide and trisaccharide. The algin lyase disclosed by the invention is stable in nature andhigh in yield, and has definite industrialized application potential.

The invention belongs to the technical field of biology, relates to an anti-human PDL1 monoclonal antibody and use thereof, and also provides a coding nucleic acid molecule, an expression vector and a host cell of the antibody, and a method for expressing the antibody. The anti-human PDL1 monoclonal antibody can specifically recognize a human PDL1 monoclonal antibody. The antibody has a higher binding affinity with human PDL1 than that of an existing anti-human PDL1 monoclonal antibody, and has a novel sequence.

The invention belongs to the technical field of biology, relates to an anti-human PDL1 monoclonal antibody and use thereof, and also provides a coding nucleic acid molecule, an expression vector and a host cell of the antibody, and a method for expressing the antibody. The anti-human PDL1 monoclonal antibody can specifically recognize a human PDL1 monoclonal antibody. The antibody has a higher binding affinity with human PDL1 than that of an existing anti-human PDL1 monoclonal antibody, and has a novel sequence.

The invention relates to an anti-human CSF-1R monoclonal antibody and application. Meanwhile, the invention provides a coding nucleic acid molecule of the antibody, an expression vector, a host cell and a method which is used for expressing the antibody. The invention further provides an antibody immunoconjugate, a bi-specific molecule, a chimeric antigen receptor, a medicine compound and application of the antibody. Compared with the prior art, the anti-human CSF-1R monoclonal antibody has the following advantages that the monoclonal antibody can specifically recognize human CSF-1R, the binding affinity of the antibody and the human CSF-1R is higher than those of existing anti-human CSF-1R monoclonal antibodies, sequences of the anti-human CSF-1R monoclonal antibody are novel, and the anti-human CSF-1R monoclonal antibody bonds a unique epitope.

The invention relates to an anti-human CSF-1R monoclonal antibody and application thereof and simultaneously discloses an encoding nucleic acid molecule, an expression vector, a host cell of the antibody and a method for expressing the antibody. The invention further provides an antibody immune coupling conjugate, a bi-specific molecule, a chimeric antigen receptor and a pharmaceutical compositionwhich contains the antibody and use. Compared with the prior art, the antibody has the advantages that the monoclonal antibody is capable of specifically recognizing human CSF-1R, the bonding affinity between the monoclonal antibody and human CSF-1R is stronger than that between an existing anti-human CSF-1R monoclonal antibody and human CSF-1R, the sequence is novel, and the monoclonal antibodyis combined with a specific epitope.

The invention provides a monoclonal antibody which can specifically recognize human OX40. The affinity of combination with the human OX40 of the antibody is stronger than that of an existing anti-human OX40 monoclonal antibody, and has relatively good heat resistance and acid-base resistance property.

The invention relates to an anti-human CSF-1R monoclonal antibody and application thereof. Meanwhile, the invention provides a coding nucleic acid molecule of the antibody, an expression vector, a host cell and a method which is used for expressing the antibody. The invention further provides an antibody immunoconjugate, a bi-specific molecule, a chimeric antigen receptor, a medicine compound andapplication of the antibody. Compared with the prior art, the anti-human CSF-1R monoclonal antibody has the following advantages that the monoclonal antibody can specifically recognize human CSF-1R, the binding affinity of the antibody and the human CSF-1R is higher than those of existing anti-human CSF-1R monoclonal antibodies, sequences of the anti-human CSF-1R monoclonal antibody are novel, andthe anti-human CSF-1R monoclonal antibody bonds a unique epitope.

The invention belongs to the field of biotechnology, relates to an anti-human PDL1 monoclonal antibody and its application, and provides a nucleic acid molecule encoding the antibody, an expression vector, a host cell, and a method for expressing the antibody. The invention can specifically recognize the monoclonal antibody of human PDL1, the binding affinity of the antibody and human PDL1 is stronger than that of the existing anti-human PDL1 monoclonal antibody, and the sequence is novel.